Floatz logo

Tislelizumab

Recurrent Uterine Corpus Carcinosarcoma

Floor Backes, MDmonoclonal_antibodyEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Recurrent Uterine Corpus Carcinosarcoma cohort.

Asset / SponsorPhaseRating
Bms-907351
National Cancer Institute (NCI)
Phase 2B
Metformin
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2CCC
Doxycycline
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2CCC
Carboplatin
Floor Backes, MD
Early Phase 1C

Same molecule, other indications

Tislelizumab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
69 / 100
View asset →
Hepatic Metastasis of Pancreatic CancerDormant
BB
Indicative ·
69 / 100
View asset →
Primary Peritoneal Cavity CancerDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →